
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
June 17th, 2025
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
June 17th, 2025
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3’25 Financial Results Report in Mid-August
June 16th, 2025
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
May 29th, 2025
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
May 29th, 2025
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
May 15th, 2025
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
May 14th, 2025
Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
April 21st, 2025
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 8th, 2025
Applied DNA Positions TR8 PGx Testing Service as Pre-emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
April 1st, 2025